Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations

The objective of this guideline is to review the efficacy and safety of transarterial embolization therapies for the treatment of HCC and to develop evidence‐based recommendations. MethodA review of the scientific literature published up to October 2013 was performed. A total of 38 studies were included. RecommendationsConsidering the evidence available to date, the CEPO recommends the following: (i) transarterial chemoembolization therapy (TACE) be considered a standard of practice for the palliative treatment of HCC in eligible patients; (ii) drug‐eluting beads (DEB)‐TACE be considered an alternative and equivalent treatment to conventional TACE in terms of oncological efficacy (overall survival) and incidence of severe toxicities; (iii) the decision to treat with TACE or DEB‐TACE be discussed in tumour boards; (iv) bland embolization (TAE) not be considered for the treatment of HCC; (v) radioembolization (TARE) not be considered outside of a clinical trial setting; and (vi) sorafenib combined with TACE not be considered outside of a clinical trial setting.
Source: HPB: official journal of the International Hepato Pancreat Biliary Association - Category: Gastroenterology Authors: Tags: Original Article Source Type: research